Compound Myopic Astigmatism Correction using a Mask In-the-Rail Excimer Laser Delivery System. Preliminary Results

Hyperopia Correction Using an Erodible Mask Excimer Laser Delivery System Coupled to an Axicon: Preliminary Results

Purpose.

This paper presents the results of the first human trial on the correction of hyperopia using an erodible mask excimer laser delivery system coupled to an axicon.

Methods.

We treated 17 eyes of 17 patients (age range 34–62 years) for the correction of +3.21 ± 1.04 D (range +1.00 to +4.00 D). The hyperopic correction was made using an erodible mask inserted on the laser optical pathway, to produce a circular ablation measuring 6.5 mm in diameter. An axicon was then used to create a blend transition zone from 6.5 mm up to 9.4 mm in diameter. Eyes were evaluated at one, three and six months after surgery.

Results.

Reepithelization was always observed by the fifth postoperative day, despite the large area of deepithelization (diameter 9.5 mm). Mean refractive error one month after treatment was −2.44 ± 1.59 D (range 0.00 to −6.50 D). Five eyes (29.4%) had a best corrected visual acuity loss more than two to three lines; all eyes showed mild annular haze not involving the central part of the cornea. Six months after treatment, mean refractive error was −0.88 ± 0.99 D (range +0.50 to −3.00 D). Compared to preoperative status, 13 eyes (76.5%) showed an improvement in uncorrected distance visual acuity (1–8 lines), and 14 eyes (82.4%) showed an improvement in uncorrected vision at reading distance (3–7 lines). Two eyes (11.7%) showed a best corrected visual acuity loss of two of three lines.

Conclusions.

These preliminary results indicate this approach is effective in reducing hyperopia, while its predictability has still to be proved in a larger treatment group with longer follow-up. A cautious approach to this technique is still advisable, especially for higher hyperopic corrections, in view of the large best corrected visual acuity loss seen in two eyes at six months.

Scraping and Mitomycin C to Treat Haze and Regression After Photorefractive Keratectomy for Myopia

PURPOSE

To evaluate the efficacy, safety, and predictability of therapeutic scraping and application of a diluted 0.02% mitomycin C solution to treat haze and regression after photorefractive keratectomy (PRK) for myopia.

METHODS

We performed a non-comparative, non-randomized retrospective study of 35 eyes of 30 patients who had previously undergone PRK for myopia and developed haze and regression after treatment. The range of refractive error after regression was -0.75 to -5.50 D (mean -2.92 D). Haze, ranging from grade 3 to 4 (scale: 0 to 4) caused a best spectacle-corrected visual acuity loss of 1 to 6 Snellen lines. All eyes were treated 6 to 12 months after PRK by scraping the stromal surface and application of a 0.02% mitomycin C solution for 2 minutes using a soaked merocel sponge. No laser ablation was performed. Corneal transparency, refractive error, and visual outcomes were evaluated over a 12-month follow-up period.

RESULTS

All eyes had significant improvement in corneal transparency. Thirty-one eyes had haze grades lower than 1, which were maintained over time. Only four eyes showed haze grades 1 to 2 and two of them needed further treatment using the same technique. At 12 months after treatment, all eyes were within +/-1.50 of original intended correction (mean 0.04 +/- 0.63 D). BSCVA improved in all eyes. No toxic effects were observed during re-epithelialization or during follow-up.

CONCLUSION

Single application of diluted mitomycin C 0.02% solution following scraping of the corneal surface was effective and safe in treating haze and regression after PRK.

Evaluation of the prophylactic use of mitomycin-C to inhibit haze formation after photorefractive keratectomy

PURPOSE

To evaluate the results of the prophylactic use of mitomycin-C to inhibit haze formation after excimer laser photorefractive keratectomy (PRK) for medium and high myopia in eyes that were not good candidates for laser in situ keratomileusis (LASIK).

SETTING

Carones Ophthalmology Center, Milan, Italy.

METHODS

This prospective randomized masked study comprised 60 consecutive eyes (60 patients). The inclusion criteria were a spherical equivalent correction between -6.00 and -10.00 diopters (D) and inadequate corneal thickness to allow a LASIK procedure with a residual stromal thickness of more than 250 microm. The eyes were divided into 2 groups according to the randomization protocol. After PRK, the study group eyes were treated with a single intraoperative dose of mitomycin-C (0.2 mg/mL), applied topically with a soaked microsponge placed over the ablated area and maintained for 2 minutes. The control eyes did not receive this treatment. Refraction, uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), and slitlamp evidence of corneal opacity (haze) or other visible complications were evaluated.

RESULTS

No toxic or side effects were encountered postoperatively. No study group eye had a haze rate higher than 1 during the 6-month follow-up; 19 eyes (63%) in the control group did (P =.01). At 6 months, the between-group difference in the refractive outcome was statistically significant (P =.05), with 26 study group eyes (87%) and 14 control eyes (47%) within +/-0.50 D of the attempted correction. No study group eye had a BCVA loss during the follow-up; 7 control eyes had lost 1 to 3 lines at 6 months (P =.0006).

CONCLUSIONS

The prophylactic use of a diluted mitomycin-C 0.02% solution applied intraoperatively in a single dose after PRK produced lower haze rates, better UCVA and BCVA results, and more accurate refractive outcomes than those achieved in the control group.

Concomitant Effect of Topical Ubiquinone Q10 and Vitamin E to Prevent Keratocyte Apoptosis After Excimer Laser Photoablation in Rabbits

PURPOSE

To investigate in vivo whether ubiquinone Q10 together with vitamin E protects rabbit corneas from keratocyte apoptosis after excimer laser irradiation.

METHODS

Photorefractive keratectomy (PRK) was performed in both eyes of three New Zealand white rabbits. During 3 days before surgery, each right eye received four-times-daily instillation of an eye-drop solution containing ubiquinone Q10 0.20% and vitamin E 0.04%; each left eye was treated with a solution that did not contain ubiquinone or vitamin E. The central cornea was analyzed after surgery using the in situ end labelling (ISEL) technique of nicked DNA to detect DNA fragmentation. To determine the number of ISEL positive nuclei, an average of 70 random microscopic fields (five for each de-epithelialized tissue section) of 138,000 mu2 were examined in the right and left cornea samples at 250X by two different observers.

RESULTS

Light microscopic examination of the sections from corneas treated before PRK showed that cells committed to apoptosis by PRK were about 50% compared to those of untreated controls.

CONCLUSION

Treatment of rabbit eyes before PRK with ubiquinone Q10 lowered the number of apoptotic events.

Visual performance following photoastigmatic refractive keratectomy: a prospective long-term study

PURPOSE

To prospectively determine the long-term effect of excimer laser photoastigmatic refractive keratectomy (PARK) on visual performance using psychophysical assessments and to identify predictors of poor performance on the psychophysical assessments.

SETTING

University-based hospital, Stanford University, Stanford, California, USA.

METHODS

Ninety-three eyes of 56 patients with a mean of -4.98 diopters +/- 1. 80 (SD) of primary compound myopic astigmatism had PARK using the Summit Apex Plus excimer laser and an erodible mask system. Patients were prospectively evaluated 1, 3, 6, 9, 12, 18, and 24 months following the procedure. Primary outcome variables included changes in the contrast sensitivity function curve (3.0, 6.0, 12.0, 18.0 cycles per degree) under 2 standard illuminance conditions (scotopic and photopic) and changes in the best spectacle-corrected visual performance under scotopic, photopic, and glare conditions.

RESULTS

A relative decline in the contrast sensitivity function curve occurred in the early postoperative period under both scotopic and photopic conditions. This was most pronounced under photopic illuminance and at the low spatial frequencies at the 6 month visit. By 1 year, however, the mean contrast sensitivity at all spatial frequencies and all illuminance conditions had returned to the preoperative level. Further improvements beyond the preoperative level may be related to the independent analysis of retreatment eyes beyond 6 months. A higher level of attempted correction of the spherical equivalent was predictive of an elevated scotopic contrast threshold at the extreme spatial frequencies 6 months after PARK (P <.05). The attempted level of astigmatic correction was predictive of a poor best corrected visual performance under scotopic conditions at 1 month (P <.05). This effect was only temporary and by postoperative month 3, there was no predictive effect of preoperative astigmatism (P >.05).

CONCLUSIONS

Psychophysical assessments may be a more sensitive indicator of decreases in visual performance following excimer laser refractive surgery. The attempted level of correction of spherical equivalent and astigmatism may adversely affect early scotopic visual performance. Decreases in visual performance are temporary, return to normal by 12 months, and remain stable 24 months following PARK.

Photorefractive keratectomy for compound myopic astigmatism

PURPOSE

To evaluate the safety and efficacy of photorefractive keratectomy for the treatment of primary compound myopic astigmatism.

METHODS

In a prospective study, 93 eyes from 56 patients with a mean spherical equivalent of -4.98 +/- 1.80 diopters (range, -1.75 to -8.5) underwent photoastigmatic refractive keratectomy with the Summit Apex Plus excimer laser using erodible mask technology and were followed for 2 years. Primary outcome measures included an assessment of astigmatic correction through vector analysis, manifest refraction, uncorrected visual acuity, corneal clarity, and the presence of adverse symptoms.

RESULTS

Eighty-five eyes (91.4%) were available for analysis at 6 months. Mean spherical equivalent refraction was reduced 85% (mean, -0.75 +/- 0.85 diopter) and the target-induced astigmatism was reduced 70% (mean, 0.98 +/- 1.88 diopters). Forty-eight eyes (56%) had an uncorrected visual acuity of 20/20 or greater, whereas 70 eyes (82%) had an uncorrected visual acuity of 20/40 or greater. Twenty-four eyes (26% ) required re-treatment because of undercorrection of the spherical equivalent and astigmatic components after the 6-month follow-up. Fifty-nine of the remaining eyes were available at the 24-month visit. Mean spherical equivalent refraction was reduced to -0.39 +/- 0.72 diopter (91.8%). The target-induced astigmatism was reduced 64% from 1.74 diopters. Forty-one eyes (81.3%) were within +/-1.0 diopter of attempted spherical equivalent correction. Stability within a spherical equivalent of +/-0.5 diopter occurred after the first postoperative month. Fifty-six eyes (94.9%) had an uncorrected visual acuity of 20/40 or greater, whereas 34 eyes (57.6 %) demonstrated an uncorrected visual acuity of 20/20 or greater. One eye (1.7%) lost 2 or more lines of best spectacle-corrected visual acuity.

CONCLUSION

Photoastigmatic refractive keratectomy with the Summit Apex Plus excimer laser is a safe and effective method of reducing compound myopic astigmatism. However, higher re-treatment rates may result from significant undercorrections because of current laser algorithms and variability in the mean angle of error.

Surgically induced astigmatism after photorefractive keratectomy with the excimer laser

PURPOSE

To evaluate retrospectively the effect of spherical excimer laser photorefractive keratectomy (PRK) on astigmatism.

METHODS

Four hundred seventy consecutive eyes of patients who had PRK for the treatment of myopia without astigmatic keratotomy, PRK reoperation, or other surgical procedures were evaluated in a retrospective clinical study. PRK was performed using the Summit Apex excimer laser with attempted corrections from 1 to 7 diopters (D) of myopia. Preoperative and postoperative astigmatism was determined by manifest refraction refined with a 0.25-D Jackson cross cylinder and evaluated with vector analysis.

RESULTS

Eighty-five ( 18%) eyes continued to have a spherical refraction after PRK, 53 (11%) eyes had the same preoperative astigmatism, and 332 (71%) eyes had a change in magnitude of astigmatism > or =0.25 D after spherical PRK. The absolute change in astigmatism magnitude irrespective of axis was +0.4 +/- 0.4 (standard deviation) D at 6 months after PRK. Eyes with change in astigmatism power tended to have higher preoperative myopia and higher preoperative astigmatism. Vector analysis revealed surgically induced astigmatism was 0.68 +/- 0.50 D (range, 0-3.25 D) at 1 month and 0.56 +/- 0.47 D (range, 0-3.1 D) at 12 months after spherical PRK.

CONCLUSION

Spherical excimer laser PRK is associated with significant surgically induced astigmatism that is likely related to decentration of the ablation, excimer laser beam irregularities, and variations in wound healing across the ablated zone. Surgically induced astigmatism will complicate attempts to correct astigmatism simultaneously at the time of PRK and suggest that such attempts are likely to be problematic for lower levels of astigmatism.

Prevention of corneal keratocyte apoptosis after argon fluoride excimer laser irradiation with the free radical scavenger ubiquinone Q10

PURPOSE

To assess in vitro the potential of the free radical scavenger ubiquinone Q10 in preventing keratocyte apoptosis after argon fluoride (ArF) excimer laser irradiation.

METHODS

Cultured rabbit keratocytes were irradiated at very low single-pulse laser fluences. The cumulative effects generated by three total fluence doses between 12 and 45 mJ/cm2, representative of single-pulse subablative doses during photorefractive keratectomy (PRK) in humans, were evaluated. We employed the following parameters to compare pretreated (10 microM ubiquinone Q10) and untreated samples: 1) number and morphology of living cells by Trypan blue test and ultramicroscopy, respectively; 2) level of free-radical formation assessed by malonaldehyde quantitation; 3) cellular energy level evaluated by ATP assay.

RESULTS

Excimer laser irradiation kills cultured keratocytes by inducing apoptosis. The effect increases with the cumulative fluence dose. In the samples pretreated with ubiquinone Q10 there were significantly fewer cumulative apoptotic events than in the untreated ones. Quantitative analysis of malonaldehyde cellular levels suggested this protective action of ubiquinone Q10 was connected with its ability to scavenge laser-generated free radicals. ATP assay also confirmed that it raised cellular energy levels.

CONCLUSIONS

The treatment of corneal keratocytes with relatively low concentrations of ubiquinone Q10 can prevent apoptosis after ArF excimer laser irradiation. If these findings are confirmed on human keratocytes this treatment could be usefully exploited in the PRK surgical procedure. That might lead to a reduction in the occurrence of haze and curvature regression triggered by programmed cell death.

Photorefractive Keratectomy for Hyperopia Using an Erodible Disc and Axicon Lens: 2-Year Results

BACKGROUND

This paper presents the results over a 2-year follow-up of the first human trial of photorefractive keratectomy (PRK) for correction of hyperopia using an erodible disc excimer laser delivery system (Summit) coupled to an axicon lens.

METHODS

We treated 25 eyes of 21 patients for a mean correction of +3.38 +/- 0.97 D (range, +1.00 to +4.00 D). The hyperopic correction was made using an erodible disc inserted on the laser optical pathway; an axicon lens was then used to create a blend transition zone. Eyes were evaluated at 1, 3, 6, and 12 months after surgery. For a smaller series of 11 eyes, we also present 24-month results.

RESULTS

Mean refractive error 1 month after treatment (25 eyes) was -2.35 +/- 1.55 D (range, +1.00 to -6.50 D). Eight eyes (32%) had a spectacle-corrected visual acuity loss greater than 1 line. Twelve months after treatment, mean spherical equivalent refraction was -0.47 +/- 0.80 D (range, +1.25 to -2.25 D). Nineteen eyes showed an improvement (range, 3 to 8 lines) in uncorrected distance visual acuity and 23 showed improvement in uncorrected vision at reading distance (1 to 7 lines).

CONCLUSION

This technique proved effective in reducing hyperopia, but predictability must be demonstrated in a larger treatment group. Safety was confirmed by the absence of delayed reepithelialization and the absence of spectacle-corrected visual acuity loss greater than 1 line at 1 year after surgery.

Excimer laser correction of astigmatism with multipass/multizone treatment. The Melbourne Excimer Laser Group

PURPOSE

To evaluate the accuracy of excimer laser correction of myopic astigmatism by multipass/multizone photoastigmatic refractive keratectomy (PARK).

SETTING

Tertiary referral ophthalmic hospital with an associated private laser facility.

METHODS

This study comprised a consecutive series of 332 eyes of 289 patients who were followed for 6 months. All patients were 18 years or older, had stable myopic astigmatism (up to a -19.0 diopters [D] spherical equivalent [SE] at the spectacle plane), and had a best corrected visual acuity of at least 20/60 in both eyes. All eyes were treated with a VISX Twenty-Twenty excimer laser. The correction was divided between ablation zones using a multipass/multizone treatment paradigm based on the amount of myopia and astigmatism. Patients were examined 1 week, and 1, 3, and 6 months after surgery.

RESULTS

Analysis of the mean percentage of spherical correction across the range of myopic preoperative SEs treated demonstrated 90% correction for most amounts of myopic astigmatism. Eyes with low myopia (mean preoperative SE < or = -5.0 D) treated with < or = -1.0 diopter cylinder (DC) of astigmatism achieved a mean percentage of spherical correction of 91% versus 93% in eyes with high myopia (> -5.0 D mean preoperative SE). Eyes with low myopia treated with > -1.0 DC of astigmatism achieved a mean percentage spherical correction of 90% versus 89% in eyes with high myopia. The differences between the two groups were not statistically significant. Patients with high relative cylinder (> 80% of total sphere treated) achieved comparable results. Analysis of the astigmatic component of the treatment, independent of the spherical result, showed a trend toward overcorrection in the high myopia group with less than -1.0 DC and a mean astigmatic correction of 89 and 98%, respectively, in the low and high myopic astigmatism groups. The mean angle of error was +2.0 degrees.

CONCLUSION

Multipass/multizone PARK for myopic astigmatism demonstrated a high degree of predictability and stability with desirable results for low and high levels of astigmatism across the range of myopic astigmatism treated by surface ablation.